No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
|Articles|September 11, 2017
How do you give back?
September 5 was declared International Day of Charity. How do you, your staff or your business give back to your community or the industry? Share your stories with us here!
Advertisement
for poll
Advertisement
Related to this article
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
At week 112, at least 72% of patients on icotrokinra held PASI 90 and at least 44% held PASI 100, with no new safety signals reported.
Raj Chovatiya, MD, PhD, MSCI, discusses the FDA approval of remibrutinib for symptomatic dermographism and what an on-label option means for patients.
By week 36, combination therapy altered 482 proteins and 467 genes vs 140 and 16 with ixekizumab alone in exploratory TOGETHER-PsO data.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
The supplemental New Drug Application seeks to expand the use of Ameluz with red light photodynamic therapy beyond the face and scalp to actinic keratoses on the extremities, neck, and trunk.
The 4-day CME meeting in Las Vegas offers up to 24.25 credits and sessions on inflammatory skin disease, skin cancer, pediatric dermatology, aesthetics, and more.
Advertisement
Advertisement
Trending on Dermatology Times
1
Ixekizumab Plus Tirzepatide Shifts Biomarkers in Psoriasis with Obesity
2
Upadacitinib Shows Broader Inflammatory Effects and Earlier Skin Barrier Restoration Than Dupilumab in Atopic Dermatitis
3
Nemolizumab Maintains Deep Skin and Itch Responses Through 3 Years in Atopic Dermatitis
4
Augmented Intelligence in Skin Cancer Detection and Prognosis
5